english.prescrire.org > Prescrire International > N°103 - October 2009

n°103

October 2009

Issue Contents
Editorial

Free  Black wall of secrecy

p.192
Drug agencies fail the transparency test

Marketing Authorisations

Prasugrel (after angioplasty and stenting) (New Indication)

p.193-195
Continue to use aspirin + clopidogrel

INN common stems - Gene therapy: two-word INNs

p.195

Lacosamide (refractory partial epilepsy) (New Drug)

p.196
It's better to optimise existing combinations

Rotigotine (restless legs syndrome) (New Indication)

p.197
Not acceptable

Desvenlafaxine (withdrawal of marketing application for depression) (Application Withdrawal)

p.197
A welcome move

Tocilizumab (rheumatoid arthritis) (New Drug)

p.198-201
No therapeutic advantage

Lamotrigine (bipolar disorder) (New Indication)

p.201
Lithium should be tried first

Ustekinumab (psoriasis patients) (New Drug)

p.202-204
Suspicion of carcinogenicity: too risky

Fentanyl buccal tablets (cancer with breakthrough pain) (New Formulation)

p.205
Another buccal form with minimal evaluation

Moxifloxacin (in ENT and respiratory infections) (New Indication)

p.206
Inadequate restriction of indications

Moxifloxacin (gynaecological infections) (New Indication)

p.207
Do not use

Adverse Effects

Drug-induced photosensitivity

p.208-211
Many drugs increase cutaneous sensitivity to ultraviolet radiation

Metoclopramide: tardive dyskinesia

p.211
Beware long-term use

Antibiotics and asthma in children

p.212
Increased risk of asthma with antibiotics

Free  Fewer adverse effects with doxycycline than with minocycline

p.213
Minocycline has a less favourable risk-benefit balance

Use the INN to avoid confusion between drugs

p.214
Medication errors leading to severe haemorrhages

Artificial food colouring and hyperactivity symptoms in children

p.215
Consistent data

Tinzaparin: excess mortality in elderly patients with renal failure

p.216
Unfractionated heparin is best in this setting

Strontium: confusion and hallucinations

p.216
In addition to the known risks of muscle damage, etc.

Proton pump inhibitors and fractures

p.216
Increase in hip fractures after exposure of more than one year

Hospitalisation for drug-related adverse effects in France

p.216
A nationwide survey

Reviews

Renal colic in adults

p.217-221
NSAIDs and morphine are effective for pain relief

Prescrire's advice

p.221
Pain relief for adults with renal colic

Alcohol dependence: after the withdrawal phase

p.222-223

Prescrire's advice

p.223
Helping alcohol-dependent patients after the withdrawal phase

Dietary measures for type 2 diabetes

p.224
No foods off-limits

Prescrire's advice

p.224
Dietary advice for patients with type 2 diabetes

PSA-based screening for localised prostate cancer

p.225
Not currently justified

Cannabis derivatives and pain

p.226
A small role in multiple sclerosis

Outlook

Free  Editorial - Europe: patents limit access to medication

p.227

Free  Legal obligations for transparency at the European Medicines Agency: Prescrire's assessment over four years

p.228-233

Free  Censorship masquerading as transparency: the EMEA assessment report on rimonabant

p.231

Bias in company-sponsored epidemiological studies

p.234

Free  The EMEA should stop promoting brand names

p.234

Free  Self-references

p.236

Masthead

Free  Masthead

p.190

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe